Roche's IgAN Hopeful Sefaxersen Passes Phase 3 Test

Roche, Ionis RNA drug scores in kidney disease study

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers. 

Roche's IgAN hopeful sefaxersen passes phase 3 test

Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

CARLSBAD, Calif.--(BUSINESS WIRE)--Sep 23, 2026-

Roche Reports Phase III IMAgINATION Study Meets Primary Endpoint for Investigational Sefaxersen in IgA Nephropathy

(IN BRIEF) Roche has reported positive prespecified interim results from the Phase III IMAgINATION study of investigational sefaxersen in adults with primary IgA nephropathy. The trial met its primary endpoint, with sefaxersen producing statistically significant and clinically meaningful reductions in … Read the full press release →

Ionis Phase 3 sefaxersen trial meets IgAN endpoint

Ionis and Roche say sefaxersen met the week-37 Phase 3 urine protein endpoint in 459 patients; effect size and arm-level safety remain undisclosed.

Roche hits Phase 3 IgAN endpoint but holds back data - European Biotechnology Magazine

Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped short of disclosing the size of the effect.